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Abstract
Background: Unintended pregnancies are a major public health problem in the United States, and intrauterine
devices (IUDs) are among the most effective reversible birth control methods available. Historically, there have
been concerns about IUD use and infection among young and/or high-risk women that may increase the risk of
pelvic inflammatory disease (PID) and subsequent infertility.
Methods: The Contraceptive CHOICE Project (CHOICE) was a prospective cohort study of over 9,000 women
14–45 years of age residing in the St. Louis area who were interested in initiating a new form of reversible
contraception. At enrollment, participants were counseled regarding long-acting contraceptive methods with the
goal of increasing awareness of all reversible methods available. Participants were also tested for Neisseria
gonorrhoeae (GC) and Chlamydia trachomatis (CT) during enrollment and were provided with contraception at
no cost for 2–3 years.
Results: We estimate the frequency of self-reported PID in new IUD users compared with women using other
contraceptive methods. Among both new IUD users who tested positive for GC and/or CT and those who tested
negative, the PID rate was 1% or below.
Conclusions: Our results demonstrate that IUD use is safe for all women, including women at high risk for
sexually transmitted infections.
Introduction
The intrauterine device (IUD) is one of the most ef-fective reversible birth control methods available to
women.1 Yet, less than 8% of women in the United States use
an IUD, making the rate of IUD use in the U.S. lower than
many other countries.2,3 The low rate of use among U.S.
women can be attributed, in part, to clinician and patient
concerns regarding IUD use and infection, especially among
young and/or high-risk women. In a national survey of 811
practicing obstetrician-gynecologists, nearly 33% responded
that IUD use increases the risk of pelvic inflammatory disease
(PID).4 Similarly, in a survey of 250 obstetrician-gynecolo-
gists in the St. Louis region, 29% reported that an IUD causes
an increased risk of PID, 38% stated that IUDs were inap-
propriate for nulliparous women, and 67%would not provide
IUDs to adolescents.5
The Dalkon Shield, an intrauterine device available in the
1970s, was associated with increased risk of infection due to
its braided, polyfilament tail. Many clinicians still associate
any IUD with an elevated risk of infection and resulting in-
fertility. However, modern IUDs, such as the Copper T380A
IUD (Cu-IUD) and levonorgestrel intrauterine system (LNG-
IUS), have monofilament tails and have been shown to have
relatively low rates of infectious complications.6
Several international studies have found the PID rate in
IUD users to be no different than nonusers after the first 20
days following insertion.7–10 A meta-analysis by the World
Health Organization found the overall rate of PID in IUD
users to be 1.6 per 1,000 women-years of use among studies
with up to 8 years of follow-up.11 The authors found that PID
risk was more than 6 times higher during the 20 days after
insertion than during later times; and reported an unadjusted
rate for PID risk of 9.7 per 1,000 woman-years for the first 20
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days after insertion. A study in Kenya of 615 participants
found that among women without cervical infection at the
time of IUD insertion, 0.4% were diagnosed with PID com-
pared with 3.1% among women with a cervical infection.12
Another study reported 2 of 29 women with Chlamydia tra-
chomatis infection at the time of IUD insertion developed
PID.13 Data from studies done in multiple African countries
estimate the risk of PID attributable to IUD to be 0.15% (1.5
per 1,000).14,15 Finally, the annual rate of PID among pri-
vately insured women in the U.S., regardless of birth control
method, was 236 per 100,000 enrollees (2.36 per 1,000) in
2005.16
The presence of mucopurulent cervicitis or current Neis-
seria gonorrhoeae (GC) and/or Chlamydia trachomatis (CT)
infection are considered to be contraindications to IUD in-
sertion. In fact, the Centers for Disease Control and Pre-
vention (CDC) U.S. Medical Eligibility Criteria describes
this scenario as category 4, representing an ‘‘unacceptable
health risk.’’17 Data on modern IUD users and infectious
morbidity in the U.S. are scarce, especially from large cohort
studies using contemporary IUDs with systematic follow-up.
The Contraceptive CHOICE Project is one of the largest
cohorts of modern IUD users in the U.S., with over 5,000
IUD users. The objective of this report is to estimate the rate
of self-reported PID in new IUD users. We compared the
PID rate in women testing positive for GC and/or CT to
women testing negative for both infections, and made the
same comparison in women using other contraceptive
methods. We hypothesized that the PID rate in IUD users
was low, even among women testing positive for STIs
at baseline.
Methods
This is a secondary analysis of data collected in the Con-
traceptive CHOICE Project (CHOICE), which sought to
promote the use of long-acting reversible contraception, in-
cluding LNG-IUS, Cu-IUD, and subdermal implant, and to
reduce the number of unintended pregnancies in the St. Louis
region. The project was an observational cohort study of
9,256 women that removed access, education, and financial
barriers to contraception. CHOICE provided each participant
with reversible contraception of her preference at no cost for
2–3 years. The Washington University in St. Louis School of
Medicine Human Research Protection Office approved the
CHOICE protocol before participant recruitment began. A
detailed description of the CHOICE methods was previously
reported.18
The study population enrolled in CHOICE was a conve-
nience sample of women who met the following inclusion
criteria: (1) aged 14–45 years; (2) resident of the St. Louis
region; (3) English or Spanish as a primary language; (4)
sexually active with a male partner in the past 6 months or
anticipated sexual activity in the next 6 months; (5) did not
desire pregnancy in the next year; and (6) not currently using
a contraceptive method or interested in starting a new re-
versible contraceptive method.
CHOICE recruited participants between August 2007 and
September 2011 from community health centers, private
medical providers, newspaper reports, study flyers, and word
of mouth. The recruitment sites consisted of university-
affiliated clinics and providers, two facilities providing
abortions services, and community clinics providing family
planning, obstetric, gynecologic, and primary care. During
enrollment, participants were provided standardized contra-
ceptive counseling by research assistants. After written in-
formed consent was obtained, participants completed a
structured survey and were screened for CT, GC, and Tri-
chomonas vaginalis (TV).
Because all women in CHOICE were offered GC and CT
testing at the time of enrollment, positive test results implied
an infection was present at IUD insertion. Participants who
tested positive were treated with a CDC-approved antibiotic
regimen with the IUD in place. Most women began the an-
tibiotic regimen within 2–3 weeks of testing, and all were
offered screening for reinfection after treatment. The one
exception to the above was if mucopurulent cervicitis was
present at the time of initial planned insertion. In these rare
cases, women were first treated for GC and/or CT and re-
turned after treatment for IUD insertion.
Telephone interviews were conducted at 3 and 6 months
and every 6 months post enrollment for the duration of study
participation. We collected data regarding method use, clin-
ical signs and symptoms, STI diagnosis, and pregnancy. At
each interview, participants were asked, ‘‘[s]ince we last
spoke, have you been told by a health care provider that you
had pelvic inflammatory disease (PID) (or an infection of the
tubes, ovaries, or uterus)?’’ Because the investigators were
aware of additional PID cases that may have occurred in
participants that did not respond to the 3- or 6-month survey,
we also reviewed the CHOICE adverse event log for women
calling or presenting with signs or symptoms of infection.
We reviewed the available medical records of all patients
who self-reported PID in the 3- or 6-month telephone survey
or cases discovered from the adverse event log. If a patient
was seen at an outside clinic or emergency department, we
attempted to obtain medical records from the visit for con-
firmation of the diagnosis. Medical records were reviewed by
two physicians (TM and JP) and rated as ‘‘likely PID,’’
‘‘possible PID,’’ or ‘‘not PID.’’ Cases were considered
‘‘likely PID’’ if medical records documented abdominal or
pelvic pain and/or tenderness on exam and a positive STI or
other findings (e.g., tubo-ovarian abscess) that indicated a
high likelihood of PID. Any participant presenting with signs
and/or symptoms of pelvic infection (e.g., abdominal pain,
pelvic tenderness, abnormal vaginal discharge, etc.) and no
other obvious etiology was considered ‘‘possible PID.’’
Medical records could not be obtained in four cases, and these
participants were considered ‘‘possible PID.’’ If no pelvic
tenderness was noted on exam or the evaluating clinician
communicated to the study team that the patient did not have
PID, we considered these cases as ‘‘not PID.’’ Evaluation
discrepancies were discussed, and a consensus was reached
regarding PID classification.
For this analysis, we included participants for whom we
had baseline GC and/or CT test results and survey follow-up
data at 3 or 6 months. We included all women who started
their baseline chosen method within the first 9 weeks of en-
rollment; 93% of participants started their chosen method
within 4 weeks of enrollment.We calculated the self-reported
rate of PID reported in the 3- and 6-month surveys among
IUD users (LNG-IUS and Cu-IUD) and stratified this group
by whether their baseline test for GC and/or CT was positive.
We also compared these rates with the rate in non-IUD users
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(oral contraceptive pill [OCP], contraceptive patch, vaginal
ring, implant, and depot medroxyprogesterone acetate
[DMPA]). Only women who started their non-IUD contra-
ceptive method within the first 9 weeks of their enrollment
were included in the non-IUD category; therefore, women
using no method were excluded. The PID rate was calculated
using the number of PID cases divided by the number of
users.
Results
The baseline characteristics of the 7,611 CHOICE partici-
pants who responded to PID questions during the 3 or 6-month
telephone survey and had baseline GC and/or CT results are
presented in Table 1. Half (48.8%) of the participants self-
identified as black and 43.5% as white. The mean age of
participants was 25.2 years. More than half of the partici-
pants (56.1%) reported receiving government support (food,
stamps, Women, Infants, and Children Supplemental Nu-
trition program, welfare, and/or unemployment) or having
trouble paying for food, transportation, healthcare, and/or
housing. A history of STI was common among our cohort:
3,046 (40.0%) of participants reported a history of STI, and
552 (7.3%) tested positive for an STI (GC, CT, or TV) at the
baseline enrollment visit. Over one-third (35.4%) reported a
history of abortion. The median total lifetime sex partners
was 6, and 410 (5.5%) of the participants reported having
more than one male sex partner in the past 30 days at en-
rollment. Approximately one-quarter (23.1%) reported cur-
rent smoking, and 19.3% reported drug use in the past 30
days at enrollment.
Table 1 also provides baseline characteristics by baseline
chosen method, IUD (n= 4,371) versus non-IUD users
(n= 3,240). The mean age was higher among IUD users (26.4
years) than non-IUD users (23.7 years, p< 0.01). Although
IUD users were equally likely to be black or white, non-IUD
users were more likely to be black. Participants who chose an
IUD reported more total lifetime sex partners than non-IUD
users: median of 6 versus 5 ( p< 0.01). IUD users were more
likely to report never using condoms than non-IUD users
(41.9% vs. 29.7; p< 0.01), and less likely to report using con-
doms every time (33.8% vs. 40.0%; p< 0.01). IUD users were
more likely to report a history of STI than non-IUD users
(41.2% vs. 38.4%; p= 0.01), being a current smoker (24.1% vs.
21.8%), and receiving government support or having trouble
paying for basic necessities (57.0% vs. 54.7%).
We identified 33 PID cases among the 7,611 participants
included in this analysis. Upon subsequent review, 10 did not
have PID. Of the 23 remaining participants, we categorized 6
as ‘‘likely PID’’ and 17 as ‘‘possible PID.’’ Table 2 shows the
rate of PID by IUD use, and also stratified by baseline GC/CT
status. We found both the self-reported rate of PID among
IUD and non-IUD users in the first 6 months to be near or
below 1%. The self-reported PID rate by 6 months was 0.46%
among all IUD users (95% confidence interval 0.26%–
0.66%) and 0.09% among all non-IUD users (95% confi-
dence interval 0%–0.20%). We were conservative in our
approach and included the ‘‘possible PID’’ and ‘‘likely PID’’
cases as PID. If we only include ‘‘likely PID’’ cases, the rate
of PID in IUD users would decrease from 0.46% to 0.14%.
Among participants who tested positive for GC and/or CT
at baseline, the PID rate among IUD users and non-IUD users
were 1.10% and 0% respectively ( p = 0.42). Among patients
with negative baseline GC and CT tests, the PID rates in IUD
and non-IUD users were 0.44% and 0.10% respectively
( p = 0.008).
Discussion
We found that the rate of PID was higher in the IUD group
than the non-IUD group. However, the occurrence of PID in
both IUD and non-IUD users was rare. The rates of PID in
IUD and non-IUD users who had tested positive for GC and/
or CT at baseline were 1% or less. The low rate of PID among
women testing positive for GC and/or CT may be attributed
to their prompt antibiotic treatment. Among participants who
tested negative for GC and/or CT at baseline, both IUD
and non-IUD users reported rates of PID that were well
below 1%.
A World Health Organization (WHO) meta-analysis of 12
randomized studies comparing two or more types of IUDs
found the overall rate of PID to be 1.6 per 1,000 woman-
years.11 The meta-analysis included 22,908 IUD insertions
and reported 81 cases of PID (0.35% of insertions) with
51,339 woman-years of follow-up. After the first 20 days post
insertion, the PID incidence was 1.4 per 1,000 woman-years;
however, the PID rate within the first 20 days of insertion was
9.7 per 1,000 woman-years. If we convert the observed
0.46% of IUD users who were diagnosed with PID by 6
months to a rate per 1,000 woman-years, it would approxi-
mately be 9.2 per 1,000 woman-years. This is very similar to
the findings from the WHO meta-analysis.
Because PID rates are not consistent over time after IUD
insertion, we should consider the duration of follow-up time
when comparing rates from different studies. Several other
international studies have found the incidence of PID in IUD
users to be statistically similar to that in nonusers after the
first 20 days following insertion.7–10 In our study, when an-
alyzed by type of IUD, the rate of PID for the Cu-IUD was
0.58 per 1,000 woman-years (with 2,795 insertions), and
there were no PID cases in women using the LNG-IUS (1,552
insertions). A meta-analysis of studies done in multiple Af-
rican countries with high STI prevalence estimated the risk of
PID attributable to IUD to be 1.5 per 1,000 women at high-
risk of STI.14,15 The same meta-analysis cited a smaller study
that estimated the risk of symptomatic PID after IUD inser-
tion during CT and/or GC infection to be 3.1%.12
The Contraceptive CHOICE Project contains the largest
prospective cohort of IUD users in the U.S. Thus, strengths of
this study include the large number of IUD users and the
systematic, prospective assessment. Our analysis relied on a
combination of data sources to capture PID cases: (1) self-
reported PID by study participants in response to a survey
question; (2) unscheduled calls to study staff to report PID or
signs/symptoms of infection; or (3) during a visit to the study
clinic. However, we attempted to assess false positive cases
by reviewing participant medical records, when available.
We used a liberal case definition for PID and therefore may
have included cases that were not truly PID. In addition, we
had four cases of self-reported PID for which we could not
locate supporting medical record documentation. We were
conservative in our approach and included these ‘‘possible
PID’’ cases as PID. Thus, our rate is most likely an overes-
timate of the true rate of PID among IUD users.
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Table 1. Participant Baseline Characteristics by Baseline Chosen Method
Total (n = 7,611) Non-IUD (n = 3,240) IUD (n= 4,371) pa
Mean SD Mean SD Mean SD
Age 25.2 5.9 23.7 5.4 26.4 5.9 < 0.01
Median Range Median Range Median Range
Total lifetime sex partners 6 0–308 5 0–308 6 0–215 < 0.01
n % n % n %
Race < 0.01
Black 3713 48.8 1730 53.4 1983 45.4
White 3310 43.5 1249 38.6 2061 47.2
Others 587 7.7 260 8.0 327 7.5
History of STIb 0.01
No 4565 60.0 1996 61.6 2569 58.8
Yes 3046 40.0 1244 38.4 1802 41.2
Any STI at baselinec 0.01
No 7059 92.7 2964 91.5 4095 93.7
Yes 552 7.3 276 8.5 276 6.3
Ever abortion at baseline < 0.01
No 4920 64.6 2195 67.7 2725 62.3
Yes 2691 35.4 1045 32.3 1646 37.7
Gravidity < 0.01
No 2432 32.0 1326 40.9 1106 25.3
Yes 5179 68.0 1914 59.1 3265 74.7
More than 1 partner in last 30 days 0.02
No 7106 94.5 2979 93.9 4127 95.0
Yes 410 5.5 195 6.1 215 5.0
Condom use with all partners in last 30 daysd < 0.01
Every time 1997 36.4 917 40.0 1080 33.8
Almost every time 623 11.4 303 13.2 320 10.0
Sometimes 537 9.8 245 10.7 292 9.1
Almost never 309 5.6 148 6.5 161 5.0
Never 2019 36.8 680 29.7 1339 41.9
Public support or trouble paying
for basic necessities
0.04
No 3345 43.9 1467 45.3 1878 43.0
Yes 4266 56.1 1773 54.7 2493 57.0
Health care in last 12 months < 0.01
Yes 5977 89.1 2520 87.8 3457 90.1
No 732 10.9 351 12.2 381 9.9
Cervical cancer screening in the last year 0.13
No 932 13.2 401 13.9 531 12.7
Yes 6124 86.8 2475 86.1 3649 87.3
Currently smoker 0.02
Yes 1756 23.1 706 21.8 1050 24.1
No 5837 76.9 2529 78.2 3308 75.9
Any drug usee 0.01
No 6104 80.7 2554 79.3 3550 81.7
Yes 1463 19.3 666 20.7 797 18.3
ap-value is from comparison between IUD users and non-IUD users.
bHistory of STI includes self-reported history of chlamydia infection, gonorrhea, syphilis, trichomoniasis, genital herpes, genital warts,
human papillomavirus infection, human immunodeficiency virus infection, or pelvic inflammatory disease.
cSTI at baseline includes positive test for chlamydia, gonorrhea, trichomonas, syphilis or human immunodeficiency virus.
dNumber (n) for this variable is equal to 3,488 and represents only participants who reported having sex within the past 30 days at
enrollment.
eDrug use includes ‘‘yes’’ responses to any of the five questions asking participants if they use weed, use ecstasy, smoke/snort/swallow/
inhale any other drug, shoot up any drugs, or exchange sex for drugs.
IUD, intrauterine device; SD, standard deviation; STI, sexually transmitted infection.
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Our study is not without limitations. First, chart review is
severely limited as a diagnostic tool for PID; prospective
clinical evaluations with objective PID criteria would have
been ideal. However, clinical assessment for PID also has
significant limitations.19,20 Clinicians are more likely to di-
agnose abdominal/pelvic pain as PID in IUD users compared
with non-IUD users.21 Current guidelines for initiating
treatment of PID are sensitive but not specific, allowing for a
high rate of false positives. Women using IUDs are counseled
to be aware of pelvic pain andmay therefore be more likely to
seek healthcare and subsequently receive a diagnosis of PID.
We selected our comparison group to be women using the
implant, DMPA, OCPs, patch, or ring as our comparison
group because they represent the largest group of contra-
cepting women in the U.S.; 34.7% of reproductive-age
American women using contraception use one of these
methods according to the latest National Survey of Family
Growth.22 We considered classifying condom users as the
comparison group, but their risk of STIs and PID is lower if
they are using a barrier method consistently and correctly.
We also considered comparing IUD users with women using
no contraception; however, women using no method are at
higher risk for STI and PID than most women, and very few
women in CHOICE chose no method at the time of enroll-
ment. We were unable to stratify our analysis by important
subgroups and potential confounding variables (e.g., smok-
ing, prior history of STI, higher total number of lifetime
sexual partners, condom use, etc.) because of the small
number of PID cases identified. Finally, women with PID
often do not have symptoms or have mild symptoms such that
relying on self-report likely underestimates PID.23
Conclusion
In a cohort of over 5,000 IUD users, we found that PID is a
rare complication of IUD use, even among women testing
positive for GC and/or CT. Clinicians should dispel the myths
and misconceptions regarding young age, IUD use, and in-
fection risk. IUDs should be offered as first-line contracep-
tive options for most women, including high-risk women. In
addition, same-day IUD insertion should be considered, as
the rate of infectious morbidity is low even in the highest risk
groups.
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